

Waning of SARS-CoV-2 antibodies targeting the Spike protein of ChAdOx1 and BNT162b2 COVID-19 vaccines and analysis of the Virus Watch community cohort

DOI: [10.1101/2021.11.05.21265968](https://doi.org/10.1101/2021.11.05.21265968)

Citation Report

#	ARTICLE	IF	CITATIONS
4	Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2381-2392.	2.7	14
5	Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults. <i>Frontiers in Aging</i> , 2022, 3, .	1.2	9
6	Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 868-874.	0.5	57
8	SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore. <i>Vaccines</i> , 2022, 10, 331.	2.1	17
9	Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants. <i>Vaccines</i> , 2022, 10, 324.	2.1	9
11	Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2022, 117, 462-469.	0.2	33
13	Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCoV-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI). <i>Journal of Infectious Diseases</i> , 2022, 226, 1877-1881.	1.9	5
15	Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. <i>Nature Communications</i> , 2022, 13, .	5.8	19
16	Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose. <i>Wellcome Open Research</i> , 0, 7, 181.	0.9	4
17	Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers – the SIREN (Sarscov2) Tj ETQq0.8 0.784314 rgBT	0.784314	4
18	Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. <i>Archives of Public Health</i> , 2022, 80, .	1.0	30
19	Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. <i>Nature Communications</i> , 2022, 13, .	5.8	15
20	SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron. <i>Viruses</i> , 2022, 14, 2336.	1.5	5
22	Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. <i>Scientific Reports</i> , 2022, 12, .	1.6	20
23	Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2 seropositive individuals. , 2023, 2, 100083.		2
24	COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates. <i>Journal of Epidemiology and Global Health</i> , 2023, 13, 67-90.	1.1	3